Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Feb 12;178(4):425-7.
doi: 10.1503/cmaj.071592.

Mortality benefit from unrestricted access to clopidogrel: too good to be true?

Samy Suissa  1
Affiliations
Review

Mortality benefit from unrestricted access to clopidogrel: too good to be true?

Samy Suissa. CMAJ. .
No abstract available

PubMed Disclaimer

Figures

None
Figure 1: Immortal time in the study by Sheehy and colleagues of restrictive access to clopidogrel. Patients were grouped as follows: those with a delay of at least 1 day between filling a nonrestrictive cardiovascular drug (NRCD) prescription and a clopidogrel prescription; those who did not fill a clopidogrel prescription despite filling a nonrestricted cardiovascular drug prescription; and those who filled both prescriptions without a delay. The time between cohort entry (percutaneous coronary intervention [PCI]) and the first nonrestricted cardiovascular drug prescription (blue line) is immortal for all 3 groups because the patients must have been alive during these periods to have filled their prescriptions. The time between the nonrestricted cardiovascular drug and clopidogrel prescriptions (orange line) is also immortal for those with a delay in filling a clopidogrel prescription. Patients who died during this period were necessarily grouped with those who did not fill a clopidogrel prescription.
See this image and copyright information in PMC

Comment on

References

    1. Cannon C. Clopidogrel and percutaneous coronary intervention. Lancet 2002;359:169. - PubMed
    1. Choudhury RP. Clopidogrel and percutaneous coronary interventions [letter]. JAMA 2003;289:1925. - PubMed
    1. Bridges JFP. Clopidogrel and percutaneous coronary interventions [letter]. JAMA 2003;289:1925-6. - PubMed
    1. Sheehy O, LeLorier J, Rinfret S. Restrictive access to clopidogrel and mortality following coronary stent implantation. CMAJ 2008;178:413-20. - PMC - PubMed
    1. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007;16:241-9. - PubMed

MeSH terms